Hadassah

Israeli Biotech Co. Receives Major Grant to Further Develop Treatment for AMD

Wednesday, May 13 2015

To further develop its world-first, animal product-free stem cell treatment for age-related macular degeneration (AMD), Israel’s Cell Cure Neurosciences Ltd. has received a 6.24 million shekel (approximately $1.6 million dollar) grant from Israel's Office of the Chief Scientist (OCS).

A clinical trial using this product was initiated in February at the Hadassah Medical Organization, whose Prof. Benjamin Reubinoff, Chief Scientific Officer of Cell Cure and Director of Hadassah's Human Embryonic Stem Cell Research Center, and Prof. Eyal Banin, head of the Center for Retinal and Macular Degeneration, were instrumental in its development. The product, called OpRegen®, is a retinal pigment epithelial (RPE) cell formulation derived from human embryonic stem cells (hESCs), characterized by high purity and potency.

"We thank the Israel Office of the Chief Scientist for its commitment to innovation and for continuing support of Cell Cure and its development of a cell therapy-based treatment for a major disease of aging," said Charles Irving, PhD, Chief Executive Officer of Cell Cure.

"I join with Dr. Irving in thanking the OCS for its generous support in advancing pluripotent stem cell research into clinical applications," Prof. Reubinoff related.

The Phase I/IIa study of OpRegen® has been designed to provide preliminary, objective, functional and structural data on this cell transplantation's ability to slow the progression of geographic atrophy (dry-AMD), in addition to safety data. Dry-AMD severely impacts the quality of life of the elderly and there is as yet no approved therapy.

The clinical trial, involving four groups of patients, will evaluate three different dose regimens. Cell Cure expects to report interim data from the cohorts in the coming months. Details of the trial are available at https://clinicaltrials.gov/ct2/show/NCT02286089?term=OpRegen&rank=1

Dry AMD is the leading cause of visual impairment and blindness among the elderly in the US and other developed countries. While treatment options exist for the treatment of the wet form of AMD, 90 percent of all patients with AMD have the dry form. As Cell Cure's website explains: "The root cause of dry-AMD is believed to be the dysfunction of RPE cells. Therefore, one of the most exciting new therapeutic strategies for dry-AMD is the transplantation of healthy young RPE cells to support and replace those lost with age. Pluripotent stem cells, such as hESCs, can potentially provide a means of manufacturing such healthy RPE cells on an industrial scale."

Related Stories

alt_text

Monday, Sep 16 2019

Hadassah Australia Will Help Ethiopian Israelis Achieve Their Dream

Barely 11 percent of Ethiopian Jewish students attend university in Israel, as compared to 42 percent of their counterparts in the general population.

READ MORE ›
alt_text

Friday, Sep 6 2019

An Oasis of Peace

In the Jerusalem Post, Hadassah President Ellen Hershkin writes about Middle East peace, shared society and dignity for all.

READ MORE ›
alt_text

Friday, Sep 6 2019

New, Larger Pediatric Bone Marrow Transplant Unit Opens at Hadassah

With a $4.75-million grant from The Leona M. and Harry B. Helmsley Charitable Trust, the Hadassah Medical Organization has opened a new pediatric bone marrow transplantation...

READ MORE ›
alt_text

Friday, Sep 6 2019

Creating an Exceptional Bar Mitzvah Experience

Thirty members of the Moises Jafif family from Mexico, along with their friends, came to Israel to celebrate the Bar Mitzvah of Jak Jafif at the Kotel (the western wall of the ancient Temple Mount).

READ MORE ›
SUPPORT HADASSAH HOSPITALS

Learn more about the Hadassah Medical Organization.

Donation Questions

donorservices@hadassah.org

(800) 928-0685

Membership Questions

membership@hadassah.org

(800) 664-5646

Missions Department

missions@hadassah.org

(800) 237-1517

Contact Us

40 Wall Street

New York, NY 10005

support@hadassah.org

More ›

Show More